Chitosan‐based nanoscale systems for doxorubicin delivery: Exploring biomedical application in cancer therapy DOI
Milad Ashrafizadeh, Kiavash Hushmandi, Sepideh Mirzaei

et al.

Bioengineering & Translational Medicine, Journal Year: 2022, Volume and Issue: 8(1)

Published: Sept. 13, 2022

Green chemistry has been a growing multidisciplinary field in recent years showing great promise biomedical applications, especially for cancer therapy. Chitosan (CS) is an abundant biopolymer derived from chitin and present insects fungi. This polysaccharide favorable characteristics, including biocompatibility, biodegradability, ease of modification by enzymes chemicals. CS-based nanoparticles (CS-NPs) have shown potential the treatment other diseases, affording targeted delivery overcoming drug resistance. The current review emphasizes on application CS-NPs chemotherapeutic agent, doxorubicin (DOX), therapy as they promote internalization DOX cells prevent activity P-glycoprotein (P-gp) to reverse These nanoarchitectures can provide co-delivery with antitumor agents such curcumin cisplatin induce synergistic Furthermore, co-loading siRNA, shRNA, miRNA suppress tumor progression chemosensitivity. Various nanostructures, lipid-, carbon-, polymeric- metal-based nanoparticles, are modifiable CS delivery, while functionalization ligands hyaluronic acid promotes selectivity toward prevents demonstrate high encapsulation efficiency due protonation amine groups CS, pH-sensitive release occur. redox- light-responsive prepared treatment. Leveraging these characteristics view biocompatibility CS-NPs, we expect soon see significant progress towards clinical translation.

Language: Английский

Bioactive Synthetic Polymers DOI
Kenward Jung, Nathaniel Corrigan, Edgar H. H. Wong

et al.

Advanced Materials, Journal Year: 2021, Volume and Issue: 34(2)

Published: Oct. 5, 2021

Abstract Synthetic polymers are omnipresent in society as textiles and packaging materials, construction medicine, among many other important applications. Alternatively, natural play a crucial role sustaining life allowing organisms to adapt their environments by performing key biological functions such molecular recognition transmission of genetic information. In general, the synthetic polymer worlds completely separated due inability for perform specific functions; some cases, cause uncontrolled unwanted responses. However, owing advancement polymerization techniques recent years, new have emerged that provide targeted peptides, or present antiviral, anticancer, antimicrobial activities. this review, emergence generation bioactive bioapplications summarized. Finally, future opportunities area discussed.

Language: Английский

Citations

112
Piperidine Derivatives: Recent Advances in Synthesis and Pharmacological Applications DOI Open Access
Nikita A. Frolov, A. N. Vereshchagin

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(3), P. 2937 - 2937

Published: Feb. 2, 2023

Piperidines are among the most important synthetic fragments for designing drugs and play a significant role in pharmaceutical industry. Their derivatives present more than twenty classes of pharmaceuticals, as well alkaloids. The current review summarizes recent scientific literature on intra- intermolecular reactions leading to formation various piperidine derivatives: substituted piperidines, spiropiperidines, condensed piperidinones. Moreover, applications natural piperidines were covered, latest advances discovery biological evaluation potential containing moiety. This is designed help both novice researchers taking their first steps this field experienced scientists looking suitable substrates synthesis biologically active piperidines.

Language: Английский

Citations

82
Overcoming Cancer Drug Resistance Utilizing PROTAC Technology DOI Creative Commons

Matthew R. Burke,

Alexis R. Smith, Guangrong Zheng

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2022, Volume and Issue: 10

Published: April 25, 2022

Cancer drug resistance presents a major barrier to continued successful treatment of malignancies. Current therapies inhibiting proteins indicated in cancer progression are consistently found lose efficacy as result acquired resistance, often caused by mutated or overexpressed protein targets. By hijacking the cellular ubiquitin-proteasome degradation machinery, proteolysis-targeting chimeras (PROTACs) offer an alternative therapeutic modality treatments with various potential advantages. PROTACs specific for number known targets have been developed last 5 years, which present new options remission patients previously untreatable malignancies and provide foundation future-generation compounds. One notable advantage PROTACs, supported evidence from recent studies, is that they can overcome some mechanisms traditional targeted therapies. More recently, groups begun researching use successfully degrade conferring against first-line treatments. In this review, we focus on analyzing developments geared towards confer it search

Language: Английский

Citations

71
Checkpoint Nano‐PROTACs for Activatable Cancer Photo‐Immunotherapy DOI
Chi Zhang,

Mengke Xu,

Shasha He

et al.

Advanced Materials, Journal Year: 2022, Volume and Issue: 35(6)

Published: Nov. 25, 2022

Abstract Checkpoint immunotherapy holds great potential to treat malignancies via blocking the immunosuppressive signaling pathways, which however suffers from inefficiency and off‐target adverse effects. Herein, checkpoint nano‐proteolysis targeting chimeras (nano‐PROTACs) in combination with photodynamic tumor regression protein degradation block pathways for activatable cancer photo‐immunotherapy are reported. These nano‐PROTACs composed of a photosensitizer (protoporphyrin IX, PpIX) an Src homology 2 domain‐containing phosphatase (SHP2)‐targeting PROTAC peptide (aPRO) caspase 3‐cleavable segment. aPRO is activated by increased expression 3 cells after phototherapeutic treatment induces targeted SHP2 ubiquitin‐proteasome system. The persistent depletion blocks (CD47/SIRPα PD‐1/PD‐L1), thus reinvigorating antitumor macrophages T cells. Such strategy synergizes immunogenic phototherapy boost immune response. Thus, this study represents generalized platform modulate immune‐related improved anticancer therapy.

Language: Английский

Citations

70
AXL in cancer: a modulator of drug resistance and therapeutic target DOI Creative Commons

Yaoxiang Tang,

Hongjing Zang, Qiuyuan Wen

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2023, Volume and Issue: 42(1)

Published: June 16, 2023

Abstract AXL is a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinases family (RTKs), its abnormal expression has been linked to clinicopathological features poor prognosis cancer patients. There mounting evidence supporting AXL's role in occurrence progression cancer, as well drug resistance treatment tolerance. Recent studies revealed that reducing can weaken cells' resistance, indicating may be promising target for anti-cancer treatment. This review aims summarize structure, mechanisms regulating activating it, pattern, especially drug-resistant cancers. Additionally, we will discuss diverse functions mediating potential inhibitors

Language: Английский

Citations

47
Targeted activation of ferroptosis in colorectal cancer via LGR4 targeting overcomes acquired drug resistance DOI
Hao Zheng, Jinming Liu, Qi Cheng

et al.

Nature Cancer, Journal Year: 2024, Volume and Issue: 5(4), P. 572 - 589

Published: Jan. 30, 2024

Language: Английский

Citations

36
Bispecific antibody drug conjugates: Making 1+1>2 DOI Creative Commons
Yilin Gu, Zhijia Wang, Yuxi Wang

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2024, Volume and Issue: 14(5), P. 1965 - 1986

Published: Jan. 20, 2024

Bispecific antibody‒drug conjugates (BsADCs) represent an innovative therapeutic category amalgamating the merits of (ADCs) and bispecific antibodies (BsAbs). Positioned as next-generation ADC approach, BsADCs hold promise for ameliorating extant clinical challenges associated with ADCs, particularly pertaining to issues such poor internalization, off-target toxicity, drug resistance. Presently, ten are undergoing trials, initial findings underscore imperative ongoing refinement. This review initially delves into specific design considerations BsADCs, encompassing target selection, antibody formats, linker-payload complex. Subsequent sections delineate progress encountered by illustrated through pertinent case studies. The amalgamation BsAbs ADCs offers a prospective solution prevailing limitations ADCs. Nevertheless, symbiotic interplay among BsAb, linker, payload necessitates further optimizations coordination beyond simplistic "1 + 1" effectively surmount facing BsADC domain.

Language: Английский

Citations

34
Writers, readers, and erasers RNA modifications and drug resistance in cancer DOI Creative Commons
Di Chen, Xinyu Gu,

Yeltai Nurzat

et al.

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: Aug. 30, 2024

Drug resistance in cancer cells significantly diminishes treatment efficacy, leading to recurrence and metastasis. A critical factor contributing this is the epigenetic alteration of gene expression via RNA modifications, such as N6-methyladenosine (m6A), N1-methyladenosine (m1A), 5-methylcytosine (m5C), 7-methylguanosine (m7G), pseudouridine (Ψ), adenosine-to-inosine (A-to-I) editing. These modifications are pivotal regulating splicing, translation, transport, degradation, stability. Governed by "writers," "readers," "erasers," impact numerous biological processes progression, including cell proliferation, stemness, autophagy, invasion, apoptosis. Aberrant can lead drug adverse outcomes various cancers. Thus, targeting modification regulators offers a promising strategy for overcoming enhancing efficacy. This review consolidates recent research on role prevalent resistance, with focus m6A, m1A, m5C, m7G, Ψ, A-to-I Additionally, it examines regulatory mechanisms linked underscores existing limitations field.

Language: Английский

Citations

18
Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation DOI
Milad Ashrafizadeh, Wei Zhang, Yu Tian

et al.

Cancer and Metastasis Reviews, Journal Year: 2024, Volume and Issue: 43(1), P. 229 - 260

Published: Feb. 19, 2024

Language: Английский

Citations

17
Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy DOI Creative Commons

Xinyue Shao,

Xiaoling Zhao, Binghao Wang

et al.

Theranostics, Journal Year: 2025, Volume and Issue: 15(5), P. 1689 - 1714

Published: Jan. 2, 2025

In recent years, nano-drug delivery systems (Nano-DDS) that target the tumor microenvironment (TME) to overcome multidrug resistance (MDR) have become a research hotspot in field of cancer therapy. By precisely targeting TME and regulating its unique pathological features, such as hypoxia, weakly acidic pH, abnormally expressed proteins, etc., these Nano-DDS enable effective therapeutic agents reversal MDR. This scientific community is increasing investment development diversified exploring their anti-drug potential. Therefore, it particularly important conduct comprehensive review progress TME-targeted years. After brief introduction MDR, design principle structure liposomes, polymer micelles inorganic nanocarriers are focused on, characteristics described. It also demonstrates how break through MDR treatment various mechanisms, discusses synthetic innovation, results overcoming mechanisms. The was concluded with deliberations on key challenges future outlooks

Language: Английский

Citations

4